Navigation Links
drugstore.com inc. Achieves GAAP Profitability in the Fourth Quarter of 2007
Date:2/6/2008

18,650

Mail-order pharmacy 931 1,055 3,967 5,501

Local pick-up pharmacy 1,110 1,064 4,383 4,128

Vision 673 561 2,708 2,478

9,193 8,136 33,317 30,757

Contribution margin:

Over-the-Counter (OTC) $14,013 $10,113 $47,554 $39,640

Mail-order pharmacy 1,061 1,058 4,241 3,852

Local pick-up pharmacy 2,461 1,955 8,398 6,872

Vision 2,386 2,146 10,294 8,620

$19,921 $15,272 $70,487 $58,984

SUPPLEMENTAL INFORMATION: Reconciliation of Net Income (Loss) to Adjusted EBITDA (See Note 4 below):
Three Months Ended Twelve Months Ended

December 30, December 31, December 30, December 31,

2007 2006 2007 2006

(In thousands, unless

otherwise indicated)

Net income (loss) $156 $(2,947) $(9,011) $(13,026)

Amortization of intangible

assets 244 468 1,234 2,060

Amortization of non-cash

marketing 573 573 2,290 2,290

Stock-based compensation 1,687 1,705 8,801 6,721

Depreciation 1,761 1,540 7,504 6,040

Interest income, net (410) (438) (1,675) (1,730)

Adjusted EBITDA $4,011 $901 $9,143 $2,355

NOTE 4: Supplemental information related to the company's adjusted EBITDA

for the three and twelve months ended December 30, 2007 and

December 31, 2006 is presented for inform
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
2. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
3. drugstore.com and Revolution Health Group Announce Breakthrough Deal
4. TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience
5. Joint Commission International Achieves Accreditation from ISQua
6. Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
7. Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
10. LMS integrated obstetrics solution achieves general availability
11. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...wire-USNewswire/ -- Democratic National Committee ...atement commemorating World AIDS Day on its 20th A...com/cgi-bin/prnh/20080519/DNCLOGO ) , , "It...nd while we have made strides, much work remains t...onal and global strategy. We must focus not only ...
(Date:12/1/2008)... MassMutual Retirement Services Di...s increasing nonprofit business. Nonprofit activit...ear. , , Dan Darby joined MassMutual on De...stern region. He reports to M. Palmer Whitney, nat...sMutual,s Retirement Services Division, who will c...
(Date:12/1/2008)...ents can also trigger acute organ failure, study s...-- Antibiotics are the single largest class of dru...ury (DILI), researchers say. , The condition ac...r failure in the United States and is the most com...DILI is caused by a wide range of prescription and...
(Date:12/1/2008)...disorder (PTSD) affects as many as one in five of ...ike rape, assault, war or terrorism. It has emotio...rvivors, families. , There is no broadly accept...ng the disorder, but thanks to a Tel Aviv Universi...may be just around the corner. , Prof. Joseph Zo...
Breaking Medicine News(10 mins):Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
... of stress,a self-perpetuating cycle of factors ca...esulting weight gain often piles up around the abd...troke.This applies to both sexes.// One doctor sta...d the hazards of weight gain in midlife by learnin...
... inactivation of nitric oxide, a hormone involved ...m. If high blood pressure is left untreated, it do...iral out of control. According to the researchers ...ted on rats and found that nitric oxide, which hel...
...ltry number of human genes more than 30 per cent h... from the human genome sequence seemed scanty comp...tfly's (13,000). Michael Cooke and colleagues at t...undation in San Diego, California compared the two...
...r from lack of proper nutrition while pregnant may...earchers have found. A team from the University o... who were conceived during the Dutch famine of 194...azi occupation.// They found that the rate of obe...
Other Medicine News:
(Date:11/25/2008)...ov. 25 Poniard,Pharmace...al company focused on,innovative oncology therapi...ategic alternatives for its preclinical research p...s resources on the clinical development of picopla...he initial commercialization of,picoplatin in the...
(Date:11/25/2008)...-FirstCall/ -- CardioVascular,BioTherapeutics, In...t it has,dosed the first patient in North America...l to treat patients with severe coronary heart dis...f CORonary heart Disease) trial will include,four...s in approximately 120,patients with severe coron...
(Date:11/24/2008)...ewswire-FirstCall/ -- Leaders of Schering-Plough C... for investors on the company,s research pipeline,... includes 46 new entities in clinical trials or un...s. , , "Research and development is adding ...inue our transformation," said Fred Hassan, chairm...
(Date:11/24/2008)... Unveils Rich Development Pipeline of Compounds Me...H, N.J., Nov. 24 Scherin... top-line results of a long-term Phase III clinica...M) (asenapine) demonstrating efficacy and safety i...ial, asenapine was statistically significantly mor...
Breaking Medicine Technology:Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3Type 1 diabetes triggered by lazy regulatory T cells 3A McGill researchers 1903 1Type 1 diabetes triggered by lazy regulatory T cells 3A McGill researchers 1903 2Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 1Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 2Prominent Health Care Executive Kevin Kraushaar Joins Triadvocates LLC as Managing Principal of DC Office 9562 3Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 1Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 2Virginia Cares Uninsured Program 28VCUP 29 Announces Early Successes in Helping Uninsured Virginians Access Quality Healthcare 9559 3Health Options Inc s BlueMedicare HMO Earns NCQA Excellent Rating 9556 1Health Options Inc s BlueMedicare HMO Earns NCQA Excellent Rating 9556 2
...ER, Mass., Jun 27, 2007 (PrimeNewswire via COMTEX ... (Nasdaq:GNBT), the,leader in drug delivery for me...outh, announced today that it will be making three...f the European,Society of Pediatric Endocrinology ...t="_blank" href=,"http://www.espe2007.org/">www.es...
..., Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPha...artner Cook Medical has,completed target patient e...om a Phase II clinical trial known as Appraisal.,T...igned to study,the effect of the Neugene(R) antise...ith the placement of one or more bare metal,stents...
Other Medicine Technology:Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 2Generex Biotechnology to Make Presentations At 46th Annual Meeting,of the European Society of Pediatric Endocrinology 3AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2
The e.cam single-detector system offers general purpose scanning flexibility with unrestricted access for gurneys and wheelchairs. This cost-effective system features a clinically versatile open gant
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
Spring Type with lock. Titanium.
The REVEALRT and REVEALXVI PET/CT scanners combine our fastest PET scanner, the REVEALXL, with multi-slice spiral CT scanners from Siemens Medical Systems.
Medicine Products: